NLS COVID-19

Iconovo has signed an agreement with Immune System Regulation (ISR) for the development of an inhaled COVID-19 vaccine in Iconovo’s inhaler ICOone. The agreement is Iconovo’s second agreement within its newest strategic area innovative inhalation projects. The agreement gives ISR exclusive rights to use ICOone for the treatment of COVID-19 and its variants with a […]

Valneva has announced positive data for Part A of the Phase 1/2 clinical trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. Based on this data, the company plans to commence a Phase 3 clinical trial by the end of April 2021, subject to regulatory approval, it states in a press release. “A step closer […]

In patients with severe COVID-19, the innate immune system overreacts and this overreaction may underlie the formation of blood clots (thrombi) and deterioration in oxygen saturation that affect the patients, show researchers at Uppsala University. The findings have been published in the journal Frontiers in Immunology. A waste disposal system Blood contains numerous proteins that […]

An international research consortium has developed a ‘double antibody’ that targets two different sites of the SARS-CoV-2 virus, thereby preventing the virus from mutating to resist the therapy. The research consortium, including researchers at Karolinska Institutet, show that the antibody potently neutralizes SARS-CoV-2 and its variants and protects against COVID-19 in mice. Bispecific antibody Antibody-based […]

Pfizer is progressing to multiple ascending doses after completing the dosing of single ascending doses in a Phase 1 study in healthy adults to evaluate the safety and tolerability of an investigational, novel oral antiviral therapeutic for SARS-CoV-2. This Phase 1 trial is being conducted in the United States. The oral antiviral clinical candidate PF-07321332, […]

Valneva Sweden, currently manufacturing the cholera vaccine DUKORAL, is preparing to perform part of the production of the company’s COVID-19 vaccine, VLA2001, currently the only inactivated COVID-19 vaccine in clinical development in Europe. “Inactivated virus vaccines are historically one of the safest and most effective vaccine development strategies, with billions of patients having been vaccinated […]